The Molecular Imaging Program at Stanford (MIPS) is an inter-departmental program with the goal of advancing multimodality molecular imaging of living subjects with a particular focus on cancer. A renewal application (for years 6-10) for an in vivo cellular and molecular imaging center at Stanford (ICMIC@Stanford) P50 is now proposed. This proposal will allow continued momentum for the MIPS with a particular emphasis on clinical translation. Through significant continued investments by Stanford University in new research and clinical translational space, infrastructure, and new faculty recruitments, the MIPS are continuing to rapidly expand. Dr. Sam Gambhir, Professor of Radiology and Bioengineering, Director of MIPS, will continue to work closely with Dr. Christopher Contag, Associate Professor of Pediatrics, and Co-Director of the MIPS. Together, Drs. Gambhir (PI for this grant application) and Contag (Co-PI) form a unique leadership team that spans the breadth of disciplines involved in multimodality molecular imaging. The goal of the ICMIC@Stanford proposal is to develop state-of-the-art molecular imaging strategies for enabling cancer research and clinical translation for improved patient cancer management. Four research projects and four developmental projects spanning different components of molecular imaging research are the main science driving this grant. Two of the four research projects have specific clinical translational components that focus on predicting and monitoring response to non-small cell lung cancer (NSCLC) therapy using in vitro nano-diagnostics and molecular imaging with PET. One of the four research projects validates image-guided resection to improve outcomes for children with medulloblastoma. Another research project develops new strategies for enzyme-activated PET and MRI imaging agents. The research involves both physicians and scientists to better facilitate clinical translation. The ICMIC@Stanford investigators are from a variety of disciplines and expertise including Medical Oncology, Radiochemistry, Chemistry, Radiology, Microbiology &Immunology, Medical Physics, Bioengineering, Molecular Pharmacology and Mathematical Modeling. Three specialized resources including 1- Chemistry/Radiochemistry, 2- Small Animal Imaging, and 3- Imaging Quantitation and Analysis will help ensure that the ICMIC@Stanford grant functions efficiently. Finally, a structured training program with 2 post-docs funded by the ICMIC@Stanford with flexibility to train individuals at different career levels will ensure the ability to train next-generation interdisciplinary leaders in molecular imaging. The ICMIC@Stanford team is committed to cancer research and clinical translation of state-of-the-art molecular imaging strategies for improving clinical cancer management.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA114747-10
Application #
8726913
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (M1))
Program Officer
Menkens, Anne E
Project Start
2005-08-01
Project End
2015-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
10
Fiscal Year
2014
Total Cost
$1,926,940
Indirect Cost
$711,289
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Natarajan, Arutselvan; Patel, Chirag B; Ramakrishnan, Sindhuja et al. (2018) A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1 : Validation in Mouse Models and Human Cancer Tissues. Clin Cancer Res :
Sun, Yao; Zeng, Xiaodong; Xiao, Yuling et al. (2018) Novel dual-function near-infrared II fluorescence and PET probe for tumor delineation and image-guided surgery. Chem Sci 9:2092-2097
Natarajan, Arutselvan; Patel, Chirag B; Habte, Frezghi et al. (2018) Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. Sci Rep 8:633
Habte, Frezghi; Natarajan, Arutselvan; Paik, David S et al. (2018) Quantification of Cerenkov Luminescence Imaging (CLI) Comparable With 3-D PET Standard Measurements. Mol Imaging 17:1536012118788637
Hong, Su Hyun; Sun, Yao; Tang, Chu et al. (2017) Chelator-Free and Biocompatible Melanin Nanoplatform with Facile-Loading Gadolinium and Copper-64 for Bioimaging. Bioconjug Chem 28:1925-1930
Shen, Bin; Behera, Deepak; James, Michelle L et al. (2017) Visualizing Nerve Injury in a Neuropathic Pain Model with [18F]FTC-146 PET/MRI. Theranostics 7:2794-2805
Loft, Mathias Dyrberg; Sun, Yao; Liu, Changhao et al. (2017) Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR). Amino Acids 49:1089-1100
Natarajan, Arutselvan; Mayer, Aaron T; Reeves, Robert E et al. (2017) Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Mol Imaging Biol 19:903-914
Hori, Sharon Seiko; Lutz, Amelie M; Paulmurugan, Ramasamy et al. (2017) A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers. Cancer Res 77:2570-2584
Ronald, John A; Kim, Byung-Su; Gowrishankar, Gayatri et al. (2017) A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res 77:2893-2902

Showing the most recent 10 out of 424 publications